Assessing risk and progression of pre-diabetes and type 2 diabetes to enable disease modification.

The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment.

Our plans are built upon:
  • access to large European cohorts with comprehensive genetic analyses, rich longitudinal clinical, biochemical data and samples
  • detailed multi-omic maps of key T2D-relevant tissues and organs
  • large expertise in the development and use of novel genetic, epigenetic, biochemical and physiological experimental approaches
  • the ability to combine existing and novel data sets through effective data federation and use of these datasets in systems biology approaches towards precision medicine;
  • expertise in regulatory approval, health economics and patient engagement.

These activities will lead to the discovery of novel biomarkers for improved T2D taxonomy, to support development of pharmaceutical activities, and for use in precision medicine to improve health in Europe and worldwide.

Latest news

6 February 2017
Swiss researchers and organisations can now fully participate in the whole Horizon 2020 programme, i...
18 January 2017
The registration as well as the abstract submission system for the Joint Meeting of the EASD Islet S...
12 January 2017
The 6th meeting of the EASD-Study Group on Genetics of Diabetes (SGGD) will be held in Lei...
Stacks Image p6767_n47
Stacks Image p6767_n398
Stacks Image p6767_n51
Stacks Image p6767_n349
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115881. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097-2.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.